$SGEN Company News December pullback triggers first

New Post Public Reply Private Reply Replies (0) Message Board

Dec 7, 2013 at 12:47 PM

$SGEN Company News

December pullback triggers first technical test 11:33 a.m. Dec. 5, 2013 - Michael Ashbaugh
Six stocks to watch for some upside 2:21 p.m. April 11, 2013 - The Trading Deck
S&P 500 takes flight, reaches record territory 9:55 a.m. April 11, 2013 - Michael Ashbaugh
Five bullish charts to watch 3:15 p.m. March 7, 2013 - The Trading Deck
Thursday’s biggest movers; Apple at 5-month low 5:27 p.m. Nov. 8, 2012 - Sue Chang
Hot Stocks to watch 6:27 a.m. Aug. 9, 2012 - MarketWatch.com
2012 biotech medal winners ... so far 11:01 p.m. July 31, 2012 - Gil Morales
12 biotech stocks hit 52-week highs 2:43 p.m. July 27, 2012 - Val Brickates Kennedy
Three technical tests converge 9:40 a.m. July 18, 2012 - Michael Ashbaugh
MoKa's Morales sees Facebook, LinkedIn on cutting edge 11:34 a.m. June 25, 2012 - blogs.marketwatch.com
Tuesday’s biggest gaining and declining stocks 5:47 p.m. Feb. 14, 2012 - Sue Chang
Rackspace Hosting, Yingli rise after hours 5:44 p.m. Feb. 13, 2012 - Myra P. Saefong
Seattle Genetics falls on growth concerns 1:42 p.m. Nov. 4, 2011 - MarketWatch.com
ECB rattles the technical backdrop 9:45 a.m. Nov. 3, 2011 - Michael Ashbaugh
U.S. markets break from the “crash” range 11:19 a.m. Oct. 24, 2011 - Michael Ashbaugh
S&P 500 rattles the cage on a trend shift 9:35 a.m. Oct. 10, 2011 - Michael Ashbaugh
3 biotech stocks battle the ‘Dendreon Effect’ 6:50 p.m. Aug. 18, 2011 - Val Brickates Kennedy
Friday’s biggest gaining and declining stocks 2:49 p.m. July 15, 2011 - Kate Gibson
Seattle Genetics slides 11% on drug launch worries 9:06 a.m. July 15, 2011 - Val Brickates Kennedy
SEC sues Seattle Genetics employee over trades 12:43 p.m. Jan. 21, 2011 - Steve Goldstein

Seattle Genetics presents results from study of ADC candidate in B-cell malignancies 59 min ago - Seeking Alpha
Seattle Genetics Presents Interim Phase 1 from Novel Antibody-Drug Conjugate SGN-CD19A at ASH 2013 10:03 a.m. Today - benzinga.com
Insider Trading Alert - CTL, CNQR, EXPR, DLTR And SGEN Traded By Insiders 10:31 a.m. Dec. 6, 2013 - TheStreet.com
Top Insider Trades: SGEN RST ACCL DLTR 10:02 a.m. Dec. 6, 2013 - TheStreet.com
Seattle Genetics Inc. (SGEN): Today's Featured Drugs Winner 5:02 p.m. Dec. 3, 2013 - TheStreet.com
Bayer Eyeing Norwegian Oncology Firm - Analyst Blog 5:00 p.m. Nov. 27, 2013 - Zacks.com
A Hedge Fund is Buying Shares in These 2 Biotech Stocks 2:20 p.m. Nov. 27, 2013 - Wall St. Cheat Sheet
Four Biotech 'Surprise' Stocks for 2014 7:00 a.m. Nov. 27, 2013 - TheStreet.com
Cramer's Mad Money - 11 Things To Watch In The Week Ahead (11/22/13) 6:24 a.m. Nov. 24, 2013 - Seeking Alpha
Seattle Genetics' CEO Presents at Jefferies 2013 Global Healthcare Conference (Transcript) 9:06 a.m. Nov. 20, 2013 - Seeking Alpha
Seattle Genetics Larger Than S&P 500 Component E*trade Financial 4:41 p.m. Nov. 19, 2013 - TheStreet.com
January 2016 Options Now Available For Seattle Genetics (SGEN) 1:50 p.m. Nov. 11, 2013 - TheStreet.com
10-Q: SEATTLE GENETICS INC /WA 4:22 p.m. Nov. 8, 2013 - Edgar Online - (EDG = 10Q, 10K)
Narrower-than-Expected Loss at Seattle Genetics - Analyst Blog 3:50 p.m. Nov. 7, 2013 - Zacks.com
Seattle Genetics' CEO Discusses Q3 2013 Results - Earnings Call Transcript 10:20 p.m. Nov. 5, 2013 - Seeking Alpha
Seattle Genetics, Inc. Discusses Q3 2013 Results (Webcast) 4:25 p.m. Nov. 5, 2013 - Seeking Alpha
Immunogen's 'Smart Bomb' Cancer Drugs Are Flunking Safety Checks 9:56 a.m. Nov. 5, 2013 - TheStreet.com
The Next Great Growth Companies On Big Pharma's Radar 11:45 a.m. Nov. 4, 2013 - Seeking Alpha
CytRx Surges Ahead With Positive Drug Data 7:41 a.m. Nov. 1, 2013 - Seeking Alpha
Odds Favor Endocyte Receiving European Approval For Ovarian Cancer Drug 11:26 a.m. Oct. 30, 2013 - TheStreet.com

Seattle Genetics Presents Data from Novel Antibody-Drug Conjugate (ADC) SGN-CD19A at ASH 2013 10:00 a.m. Today - BusinessWire
Stock Price Updates, and Charitable Contributions - Research Report on BioMarin, Covidien, United Therapeutics, Brookdale, and Seattle Genetics 8:00 a.m. Dec. 4, 2013 - PR Newswire
AAAResearchReports.com Pre-Market Technical Analysis: Elan Corp., Amarin Corp., Cubist Pharmaceuticals, and Seattle Genetics 8:00 a.m. Nov. 27, 2013 - PR Newswire
Potential Acquisitions and Stock Price Updates - Research Report on BioMarin, Covidien, United Therapeutics, Brookdale, and Seattle Genetics 8:00 a.m. Nov. 26, 2013 - PR Newswire
Seattle Genetics to Present Clinical Data from Broad ADCETRIS(R) (Brentuximab Vedotin) Development Program and Novel Antibody-Drug Conjugate (ADC) SGN-CD19A at ASH 2013 9:00 a.m. Nov. 11, 2013 - BusinessWire
Critical Alerts For JPMorgan, ExOne, Target, NVIDIA, and Seattle Genetics Released By InvestorsObserver 9:31 a.m. Nov. 8, 2013 - PR Newswire
Marketing Authorization Applications, Financial Results, Product Up-gradations, and Presentations - Research Report on Baxter, Seattle Genetics, IDEXX, Hill-Rom, and BioCryst 8:00 a.m. Nov. 8, 2013 - PR Newswire
Seattle Genetics to Present at Upcoming Investor Conferences 9:00 a.m. Nov. 6, 2013 - BusinessWire
Seattle Genetics Reports Third Quarter 2013 Financial Results 4:05 p.m. Nov. 5, 2013 - BusinessWire
Morning Research: Amarin Corp. PLC, Elan Corp. PLC, Cubist Pharma Inc., and Seattle Genetics Inc. 11:34 a.m. Nov. 4, 2013 - PR Newswire
Financial Results & Release Schedules, Stock Performance Update, and New Clinical Trials - Research Report on Amgen, Boston Scientific, ACADIA Pharmaceuticals, Seattle Genetics, and Volcano 9:00 a.m. Oct. 29, 2013 - PR Newswire
Seattle Genetics Initiates Phase 1 Trial of ADC Candidate, SGN-LIV1A, for Patients with LIV-1-Positive Metastatic Breast Cancer 9:00 a.m. Oct. 21, 2013 - BusinessWire
Sales Strategies, Upcoming Financial Results Schedules, Clinical Study Updates, and FDA Agreements - Research Report on Arena, Seattle Genetics, Halozyme, Insmed, and Omeros 8:00 a.m. Oct. 21, 2013 - PR Newswire
Under AAAResearchReports.com Microscope: Amarin Corp. PLC, Elan Corp. PLC, Seattle Genetics Inc., and Cubist Pharma Inc. 11:35 a.m. Oct. 15, 2013 - PR Newswire
Seattle Genetics to Host Conference Call and Webcast Discussion of Third Quarter 2013 Financial Results on November 5, 2013 9:00 a.m. Oct. 15, 2013 - BusinessWire
Seattle Genetics Highlights ADCETRIS(R) (Brentuximab Vedotin) Clinical Data in the Frontline Setting at the International Symposium on Hodgkin Lymphoma 9:00 a.m. Oct. 11, 2013 - BusinessWire
Partnerships, Product Recall, New Contracts, Promotions, and Stock Movement - Research Report on Valeant, CareFusion, Envision Healthcare, Seattle Genetics, and Osiris 8:00 a.m. Oct. 7, 2013 - PR Newswire
Critical Alerts For Exxon Mobil, Citigroup, Dollar Tree, Oracle, and Seattle Genetics Released By InvestorsObserver 9:31 a.m. Oct. 3, 2013 - PR Newswire
Prevencio, Inc. Appoints H. Perry Fell, Ph.D., as Board Chairman and Rhonda F. Rhyne as President, Chief Executive Officer, and Board Director 9:00 a.m. Oct. 2, 2013 - BusinessWire
Seattle Genetics Announces Clinical Leadership Appointments 9:00 a.m. Oct. 2, 2013 - BusinessWire

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Don Silvestri: NFL Vet's Service Legacy Continues

More Than Just a Debt Guru It's not every day you see a former NFL player shifting gears so smoothly into the corporate world, and then to community service like a missile lock. But that's exactly what Don Silvestri, president of Debt.com, has done. Dragging a hefty reputation as a placekicker for teams like the New York Jets and the Buffalo Bills, he's now making...

Doximity Lawsuit: What Investors Need to Know Now

Lawsuit Clouds Hang Over Doximity The courtroom isn't typically where you find stocks making headlines, but Doximity's recent plunge isn't just a market hiccup. After a rough patch, an alleged misstep lands them squarely under the legal microscope, and investors have questions. Tracing Doximity's Rocky Financial Reports First, let's rewind to November last year. Doximity...

Software Updates Costly: UX Not the Biggest Culprit

Breaking Updates Trump UX Changes Here's the real scoop: software updates that break functionality are setting companies back more than those user experience (UX) tweaks that folks gripe about but usually muddle through. According to a recent LITSLINK study, even three figures that supposedly quantify UX losses turn out to be questionable at best. Real-world Disasters:...

Firehawk Defense Secures $150M, Valuation Hits $1.4B

Firehawk Defense Lands Major Funding Think about it—Firehawk Defense, a gutsy Dallas-based new-kid-on-the-block, just snagged a whopping $150 million in fresh funding. The news? Their valuation's now sitting pretty at $1.4 billion. Not peanuts, by any means. For a company in the artillery game, that's a blast of an announcement. They're predicting they'll become the big...

Red Robin Faces Board Shakeup and Financial Strategy Shift

Turbulence on the Board But Strategic Moves on Track Well, it's not every day you hear about a double departure from Red Robin's board, right on the heels of some big financial reshuffling. Two directors, James C. Pappas and Christopher Martin, decided to abandon ship effective October 23, 2026. Given their ties to JCP Investment and Jumana Capital, this isn't just a...

Flex LNG Readies for Crucial Q3 Earnings Reveal

Anticipation Builds for Flex LNG's Upcoming Q3 Reveal The air's thick with expectation as Flex LNG gears up to lay its cards on the table for the third quarter of 2026. Come November 11, the company will spill the beans on its financial dance over the last few months, promising to unfurl the numbers early in the morning like a farmer checking crops at dawn—07:00 CET...

Piramal Pharma FY27 Q2 Results: Robust Growth & Optimism

A Solid Performance from Piramal Pharma The numbers are in, and it's looking pretty good for Piramal Pharma Limited this time around. Their second quarter of fiscal year 2027 has seen some fireworks, and I'm not talking about some half-baked confetti deal. We're talking genuine growth and solid metrics here. Revenue and Profit Surge The headline? Revenue jumped a whopping...

Heritage Wines Meet Non-Alcoholic Trend: New Deal

Wine Industry Shifts Gears Well, here's a twist that might just shake up the wine racks. C. Mondavi & Family, from the historic Charles Krug estate, is aligning with Missing Thorn—a name gaining traction in the non-alcoholic wine scene. It’s a move that not only raises eyebrows but could also expand your wine-tasting options come your next sober night out. So what...

FIU Cuba Poll: Cuban American Vote Leans GOP

Here we got the latest scoop from the 2026 FIU Cuba Poll, and boy, it's a wild ride. Picture this: 76% of Cuban Americans in South Florida aren't fans of Trump’s escalated deportations of Cubans sans criminal records, yet a solid 68% are sticking to their GOP guns come election season. Now, ain't that a head-scratcher? Cuban Americans and the GOP: A Complex Relationship...

Tabañero Spices Up Holidays with $10 Gift Sets

Hot Sauce, Spicy Gifting, and Bold Barbecue When holiday cheer mixes with a dash of heat, you end up with something as electrifying as Tabañero's latest offerings. This Florida-based player is nudging its way into the gift-giving scene with a lineup that's as spicy as it is thoughtful. Frankly, if you're scrambling for stocking stuffers or a memorable Secret Santa...